Teva Pharmaceutical Industries Ltd traded at 2,960.00 this Thursday December 1st, increasing 10.00 or 0.34 percent since the previous trading session. Looking back, over the last four weeks, Teva Pharmaceutical Industries Ltd gained 6.98 percent. Over the last 12 months, its price rose by 12.12 percent. Looking ahead, we forecast Teva Pharmaceutical Industries Ltd to be priced at 2,911.24 by the end of this quarter and at 2,647.16 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Sh Fosun Pharma 36.50 0.27 0.75% -31.22%
Jiangsu Hengrui Me. 40.50 0.03 0.07% -17.68%
Guangzhou Baiy 31.01 -0.87 -2.73% 5.40%
Aspen Pharmacare 14,436.00 868.00 6.40% -38.56%
Cipla 1,120.00 -4.90 -0.44% 22.80%
Dr.Reddys Laboratories 4,516.00 41.65 0.93% -1.75%
Kalbe Farma 2,050.00 0 0% 27.33%
Richter Gedeon 8,450.00 -50.00 -0.59% -0.88%
Sun Pharmaceuticals 1,041.15 -5.30 -0.51% 38.49%
Teva Pharmaceutical Industries Ltd 2,960.00 10.00 0.34% 12.12%


Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.